Published On: Mon, Dec 15th, 2014

Alexion Pharmaceuticals Announces $500 Million Share Repurchase Program

Share This
Tags

alexianAlexion Pharmaceuticals Inc. (NASDAQ:ALXN) today announced that the Company’s Board of Directors has authorized a new share repurchase program of up to $500 million. The new share repurchase program will take effect upon completion of the Company’s current program which has approximately $22 million remaining of its previously authorized $400 million.

Alexion is a biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two debilitating ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation.

Soliris is currently approved in nearly 50 countries for the treatment of PNH and in nearly 40 countries for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris in additional severe and ultra-rare disorders beyond PNH and aHUS and is developing other highly innovative biotechnology product candidates including asfotase alfa across multiple therapeutic areas.www.alexionpharma.com.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>